Literature DB >> 27746966

Stage I lung cancer-to operate or to radiate? that is the question.

Boris Sepesi1, David C Rice1, John V Heymach2, Ara A Vaporciyan1, Stephen G Swisher1.   

Abstract

Entities:  

Year:  2016        PMID： 27746966      PMCID： PMC5059328          DOI： 10.21037/jtd.2016.08.36

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

1.  Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.

Authors:  Charles B Simone; Jay F Dorsey
Journal:  Ann Transl Med       Date:  2015-08

2.  Surgery versus SABR for resectable non-small-cell lung cancer.

Authors:  Masatsugu Hamaji; Shawn S Groth; David J Sugarbaker; Bryan M Burt
Journal:  Lancet Oncol       Date:  2015-08       Impact factor: 41.316

3.  Surgery versus SABR for resectable non-small-cell lung cancer.

Authors:  Isabelle Opitz; Gaetano Rocco; Alessandro Brunelli; Gonzalo Varela; Gilbert Massard; Walter Weder
Journal:  Lancet Oncol       Date:  2015-08       Impact factor: 41.316

4.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

5.  SABR in early operable lung cancer: time for evidence.

Authors:  Tom Treasure; Robert C Rintoul; Fergus Macbeth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

6.  STS database risk models: predictors of mortality and major morbidity for lung cancer resection.

Authors:  Benjamin D Kozower; Shubin Sheng; Sean M O'Brien; Michael J Liptay; Christine L Lau; David R Jones; David M Shahian; Cameron D Wright
Journal:  Ann Thorac Surg       Date:  2010-09       Impact factor: 4.330

7.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

8.  Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis.

Authors:  Amgad El-Sherif; William E Gooding; Ricardo Santos; Brian Pettiford; Peter F Ferson; Hiran C Fernando; Susan J Urda; James D Luketich; Rodney J Landreneau
Journal:  Ann Thorac Surg       Date:  2006-08       Impact factor: 4.330

9.  Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer.

Authors:  Joshua E Rosen; Michelle C Salazar; Zuoheng Wang; James B Yu; Roy H Decker; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa
Journal:  J Thorac Cardiovasc Surg       Date:  2016-04-07       Impact factor: 5.209

10.  Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.

Authors:  Mark S Allen; Gail E Darling; Taine T V Pechet; John D Mitchell; James E Herndon; Rodney J Landreneau; Richard I Inculet; David R Jones; Bryan F Meyers; David H Harpole; Joe B Putnam; Valerie W Rusch
Journal:  Ann Thorac Surg       Date:  2006-03       Impact factor: 4.330
View more
  1 in total

1.  1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT.

Authors:  Denise Albano; Thomas Bilfinger; Barbara Nemesure
Journal:  Lung Cancer (Auckl)       Date:  2018-08-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.